EUnetHTA Joint Action 3 (2016-20) JA3-WP4
2017 - PDF

This is the assessment of the relative effectiveness of “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)".

The final version of the assessment was published in January 2018. Below is the documentation provided by the Joint Assessment authoring team: